NEW YORK (GenomeWeb News) – Med BioGene this week said it has entered into a research collaboration and option agreement with Duke University to further develop and validate genetic biomarkers for lymphoma and leukemia.
Under the terms of the collaboration, which will use MBI’s gene expression-profiling system, Duke will provide MBI a certain number of samples from patients with clinically confirmed lymphoma and leukemia for genetic analysis.
Duke and MBI will analyze those results, and Duke will grant MBI an option to acquire exclusive worldwide licensing rights to the intellectual property developed under the collaboration.
MBI will reimburse Duke for certain expenditures, and then pay undisclosed royalties to Duke on revenue received from product sales. Duke will be entitled to publish the results of the research, subject to review by MBI.
Financial terms of the agreement were not disclosed.